Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: A cohort analysis of time patterns, sex, and other risk factors

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 483-492

  Perović Mihanović, Marta ^a   Haque, Najm S ^b   Rutherford, George W ^b   Zekan, Šime ^a   Begovac, Josip ^a,c  

^a Croatia   (Croatia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Adverse events; Antiretroviral therapy; HIV infected patients; HIV infection; Toxicity; Virologic failure

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DIDANOSINE; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; INDINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL MODIFICATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CROATIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; LIPOATROPHY; LIPOHYPERTROPHY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; POISSON DISTRIBUTION; RISK FACTOR; TIME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SEX CHARACTERISTICS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879320912     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889283     Document Type: Article

References (31)

1. Vo TT, Ledergerber B, Keiser O et al: Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis, 2008; 197: 1685-94
2. O'Brien ME, Clark RA, Besch CL et al: Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr, 2003; 34: 407-14
3. Mocroft A, Phillips AN, Soriano V et al: Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses, 2005; 21: 527-36
4. d'Arminio Monforte A, Lepri AC, Rezza G et al: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I. CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS, 2000; 14: 499-507
5. Cicconi P, Cozzi-Lepri A, Castagna A et al: Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med, 2010; 11: 104-13
6. Elzi L, Marzolini C, Furrer H et al: Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med, 2010; 170: 57-65
7. Cesar C, Shepherd BE, Krolewiecki AJ et al: Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One, 2010; 5(6): e10490
8. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH: Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med, 2006; 7: 156-62
9. Dieleman JP, Jambroes M, Gyssens IC et al: Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS, 2002; 16: 737-45
10. Glass TR, De Geest S, Weber R et al: Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr, 2006; 41: 385-92
11. Li X, Margolick JB, Conover CS et al: Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr, 2005; 38: 320-28
12. Keiser O, Fellay J, Opravil M et al: Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther, 2007; 12: 1157-64
13. Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med, 1999; 131: 81-87
14. Robison LS, Westfall AO, Mugavero MJ et al: Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses, 2008; 24: 1347-55
15. Stohr W, Back D, Dunn D et al: Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther, 2008; 13: 675-85
16. Haas DW, Ribaudo HJ, Kim RB et al: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS, 2004; 18: 2391-400
17. Mallal S, Phillips E, Carosi G et al: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med, 2008; 358: 568-79
18. Abgrall S and The Antiretroviral Therapy Cohort C: Durability of first ART regimen and risk factors for modification, interruption or death in HIVpositive patients starting ART in Europe and N. America 2002-2009. AIDS, 2013; 27: 803-13
19. Bozicevic I, Lepej SZ, Rode OD et al: Prevalence of HIV and sexually transmitted infections and patterns of recent HIV testing among men who have sex with men in Zagreb, Croatia. Sex Transm Infect, 2012; 88: 539-44
20. Kolaric B: Croatia: still a low-level HIV epidemic?-seroprevalence study. Coll Antropol, 2011; 35: 861-65
21. Bozicevic I, Begovac J: The emerging HIV epidemic among men who have sex with men in southeastern Europe. Expert Rev Anti Infect Ther, 2010; 8: 1351-58
22. Begovac J, Zekan A, Skoko-Poljak D: Twenty years of human immunodeficiency virus infection in Croatia-an epidemic that is still in an early stage. Coll Antropol, 2006; 30(Suppl.2): 17-23
23. Davidson I, Beardsell H, Smith B et al: The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study. Antiviral Res, 2010; 86: 227-29
24. Srasuebkul P, Calmy A, Zhou J et al: Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). AIDS Res Ther, 2007; 4: 18
25. Keiser O, Orrell C, Egger M et al: Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med, 2008; 5(7): e148
26. Kesselring AM, Wit FW, Sabin CA et al: Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS, 2009; 23: 1689-99
27. Bersoff-Matcha SJ, Miller WC, Aberg JA et al: Sex differences in nevirapine rash. Clin Infect Dis, 2001; 32: 124-29
28. Antinori A, Baldini F, Girardi E et al: Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS, 2001; 15: 1579-81
29. van Leth F, Andrews S, Grinsztejn B et al: The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS, 2005; 19: 463-71
30. Mocroft A, Youle M, Moore A et al: Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS, 2001; 15: 185-94
31. Thompson MA, Aberg JA, Hoy JF et al: Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA, 2012; 308: 387-402